Eris Lifesciences

Eris Lifesciences to acquire 30% stake in Swiss Parenterals for ₹423 cr

Eris Lifesciences will purchase the final 30% stake in Swiss Parenterals through a Rs 423-crore share swap, aiming for full consolidation, greater cost efficiency and strengthened strategic control

Eris Lifesciences to acquire balance 30% stake in Swiss Parenterals

Eris Lifesciences on Tuesday said its board has approved the acquisition of the remaining 30 pc stake in its subsidiary Swiss Parenterals. The proposed transaction will be effected as a share swap, through a preferential issuance of the company's shares to seller Naishadh Shah, thereby making him a shareholder and an integral part of the company's senior management team with long-term alignment, the Mumbai-based firm said in a statement. "On behalf of the shareholders of Eris, I am delighted to welcome Naishadh Shah to the community of Erisians. I am also happy to share that we propose to designate him as the Managing Director of Swiss Parenterals," Eris Lifesciences Chairman and Managing Director Amit Bakshi said. FY27 promises to be a breakout year for the company's international business, and Naishadh's continued leadership and stewardship will be pivotal to its growth, he added. Shares of Eris Lifesciences were trading 0.99 per cent down at Rs 1,665.20 apiece on the BSE.

Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26

Eris Lifesciences to leverage Novo Nordisk's exit and semaglutide patent expiry, with cartridge capacity and diabetes-focused products planned for commercialisation in FY26

Eris soars 11% on Thursday, zooms 61% from low; is it time to book profit?

The stock of the pharmaceutical company Eris Lifesciences was trading higher for the third straight day, soaring 17 per cent during the period.

Eris Lifesciences rises 4% on posting Q4 results; Check all details here

Eris Lifesciences stock advances 4 per cent as the company posts consolidated net profit for the quarter stood at ₹102 crore, rising 28 per cent YoY

Eris Life soars 13% on strong Q3 revenue; Co reduces debt ahead of guidance

The board of directors of Eris Lifesciences is scheduled to meet on Friday, February 07, 2025, to consider the declaration of interim dividend for the financial year 2024-25

Eris Lifesciences Q3FY25 results: Profit skids 18.6%, revenue up 49.6%

This quarter, the organic domestic branded formulations business grew by 12 per cent Y-o-Y, whereas revenue from the branded formulations segment grew by 35 per cent Y-o-Y

Eris Lifesciences shares drop 5% after profit slides in Q3 results; details

Eris Lifesciences share price slipped 5.35 per cent at Rs 1,181.20 a piece on the BSE in Tuesday's intraday trade after the company's net profit dropped

Eris Lifesciences Q2FY25 results: Profit skids 25.8%, revenue up 46.6%

The decline in PAT can be partly attributed to the deferred tax credit of Rs 21 crore, which the company received in the year-ago quarter

Eris Lifesciences Q2 results: Net profit declines 20% to Rs 97 crore

Eris Lifesciences on Friday said its consolidated profit after tax declined 20 per cent year-on-year to Rs 97 crore in the September quarter. The drug firm had reported a Profit After Tax (PAT) of Rs 122 crore in the July-September period of last fiscal. Revenue increased to Rs 741 crore in the second quarter compared to Rs 505 crore in the year-ago period, the company said in a statement. "The acquired businesses of Biocon and Swiss Parenterals have been integrated and are scaling up in line with our expectations," Eris Lifesciences Chairman and Managing Director Amit Bakshi said. The company is on track to achieve revenue guidance of Rs 2,600 crore in domestic formulations and Rs 3,000 crore on a consolidated basis, he added. "We continue building up our capabilities in the biologics segment. With a strategic investment in Levim Lifetech, we will become a vertically integrated Biotech player with capabilities across the value chain," Bakshi said. Shares of the company settled 0

Aster DM, Laurus Labs among 5 smallcap stock ideas in a falling market

Eris Lifesciences, BLS International and Five-Star Business are the other 3 smallcap stocks that look favourably placed on the technical charts in an otherwise weak market.

ChrysCapital exits Eris Lifesciences; sells 7.27% stake for Rs 1,187 cr

Private equity major ChrysCapital on Thursday exited Eris Lifesciences by selling its entire 7.27 per cent stake in the company for Rs 1,187 crore via open market transaction, while Infinity Partners picked up shares of the firm. Eris Lifesciences Ltd is a listed Indian pharmaceutical company and a leading player in the domestic branded formulations market. According to the block deal data available on the National Stock Exchange (NSE), ChrysCapital through its affiliate Emerald Investment Ltd sold 98,86,882 shares, amounting to a 7.27 per cent stake in Ahmedabad-based Eris Lifesciences. The shares were disposed of at an average price of Rs 1,201 apiece, taking the transaction value to Rs 1,187.41 crore. These shares were picked up by Infinity Partners at the same price, as per the data on the exchange. Shares of Eris Lifesciences rose 2.13 per cent to close at Rs 1,238.65 apiece on the NSE. Earlier this month, Eris Lifesciences said its consolidated profit after tax declined by

Biocon Q1 net profit up 551%, driven by gain from Eris Life partnership

Total revenue stood at Rs 4,567 crore in Q1 FY25 as against Rs 3,516 crore in Q1 FY24

Praj, Delta Corp: Trading strategies for 5 overbought NSE smallcap stocks

Outlook on Nifty smallcap stocks: Delta Corp, Eris Life, Praj and Usha Martin can rally up to 28 per cent, while Symphony may witness a corrective move in the near-term; suggests technical charts.

Eris Lifesciences Q4 results: Net profit rises 8.41% to Rs 70.9 crore

On a sequential basis, the company exhibited a 13.2 per cent increase in revenue; however, the PAT declined by 30.96 per cent

Biocon slips 5% on plan to sell branded formulation biz to Eris

Shares of Biocon slipped 5 per cent to Rs 254.15 on the BSE in Friday's intra-day trade as the company's unit Biocon Biologics will sell its Indian branded formulations businesses to Eris Lifesciences

Eris buys India formulation biz of Biocon Biologics for Rs 1,242 crore

The deal would enable Eris' entry into the Rs 3k cr injectables market, and it would become one of major players in the insulins segment with the acquisition of Biocon Biologic's Basalog and Insugen

Biocon to sell branded formulations biz to Eris Lifesciences for $150 mn

Biocon had earlier sold its dermatology and nephrology branded formulation businesses to Eris for Rs 350 crore in November last year

Eris Lifesciences Q3 results: Profit flat at Rs 102 crore, revenue up 16%

On a sequential basis, the company saw a 3.40 per cent decline in revenue along with Profit After Tax (PAT), which also declined by 16.77 per cent

Eris up 8% as it plans to acquire nephro, derma units of Biocon Biologics

The deal consideration is Rs 366 crore inclusive of working capital, and will be funded partly through debt financing